Previous close | 5.01 |
Open | 5.01 |
Bid | 4.10 |
Ask | 4.50 |
Strike | 17.50 |
Expiry date | 2024-05-17 |
Day's range | 5.01 - 5.01 |
Contract range | N/A |
Volume | |
Open interest | 1 |
REDWOOD CITY, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that the Compensation Committee of the Board of Directors of Pulmonx (the “Compensation Committee”) granted inducement awards consisting of a non-statutory stock option to purchase 241,409 shares of common stock and a time-based restricted stock unit award for 125,870 shares of common stock on Ma
The consensus price target hints at a 56.1% upside potential for Pulmonx (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Pulmonx Corporation ( NASDAQ:LUNG ) investors will be delighted, with the company turning in some strong numbers with...